Clinical use of aripiprazole in patients with schizophrenia: A real-life setting results from the German Postmarketing Surveillance Study

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC 1994
   Google Scholar
• Beuzen, J-N, Olausson, B, L'Italien, GL, Pans, M, McQuade, R, Carson, W. 2006a. Aripiprazole compared to standard-of-care in the management of community-treated schizophrenic patients (Schizophrenia Trial of Aripiprazole: STAR study). Presented at the 14th European Congress of PsychiatryNiceFrance
   Google Scholar
• Beuzen, J-N, Schirr, K, Pans, M, , et al. 2006b. Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Presented at the 13th Biennial Winter Workshop on Schizophrenia ResearchDavosSwitzerland
   Google Scholar
• E Brähler, Schumacher, J, Strauss, B, 2002. Diagnostische Verfahren in der Psychotherapie. Hogrefe, Göttingen
   Google Scholar
• Bristol-Myers Squibb. 2006. Abilify® Prescription information
   Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic drug, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381–389
   PubMed Web of Science ®Google Scholar
• Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006; 67: 160–161
   PubMed Web of Science ®Google Scholar
• Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766–771
   PubMed Web of Science ®Google Scholar
• Floyd M. The employment problems of people disabled by schizophrenia. J Soc Occup Med 1984; 34: 93–95
   PubMedGoogle Scholar
• Gaebel and Falkai; German Association for Psychiatry, Psychotherapy and Neurology, 2005. Treatment guideline schizophrenia. Steinkopff, Darmstadt
   Google Scholar
• Hanssens, L, Biro, E, Dillenschneider, A, Spitzerova, H, McQuade, R, Iwamoto, T. 2006. Reasons for participation and preference of medicine in community–treated schizophrenic patients in a naturalistic setting (Schizophrenia Trial of Aripiprazole: STAR study). Presented at the 14th European Congress of PsychiatryNiceFrance
   Google Scholar
• Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004; 18: 375–383
   PubMed Web of Science ®Google Scholar
• Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995; 166: 654–659
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial antagonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137–140
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–771
   PubMed Web of Science ®Google Scholar
• Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005; 62: 1305–1312
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2 (1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274: 329
   PubMed Web of Science ®Google Scholar
• Klein N, Wallner H, Kasper S. Aripiprazol – ein partieller Dopamin-Agonist als neues Antipsychotikum. Psychopharmakotherapie 2006; 13: 49–54
   Google Scholar
• Lambert M, Riedel M, Möller H-J, Naber D. Das Antipsychotikum Aripiprazol – Wirksamkeit und Verträglichkeit. Psychiatrie 2004; 1: 50–62
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353: 1209–1223
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2005; 61: 123–136
   Google Scholar
• McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazol: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 2002; 5(Suppl 1)S176
   Google Scholar
• Melle I, Friis S, Hauff E, Vaglum P. Social functioning of patients with schizophrenia in high-income welfare societies. Psychiatr Serv 2000; 51: 223–228
   PubMed Web of Science ®Google Scholar
• Möller HJ, Laux G, Kapfhammer HP. Psychiatrie und Psychotherapie. Springer, Berlin 2003
   Google Scholar
• Moos RH, Nichol AC, Moos BS. Global assessment of functioning ratings and the allocation and outcomes of mental health services. Psychiatr Serv 2002; 53: 730–737
   PubMed Web of Science ®Google Scholar
• Sadock BJ, Sadock VA. Kaplan's and Sadock's synopsis of psychiatry. Lippincott Williams and Wilkins, Philadelphia, PA 2002
   Google Scholar
• Samele C, van Os J, McKenzie K, et al. Does socioeconomic status predict course and outcome in patients with psychosis?. Soc Psychiatry Psychiatr Epidemiol 2001; 36: 573–581
   PubMedGoogle Scholar
• Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berlin) 2000; 152: 174–180
   PubMed Web of Science ®Google Scholar
• Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol 2002; 41: 417–422
   PubMed Web of Science ®Google Scholar
• Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006; 84: 77–89
   PubMed Web of Science ®Google Scholar
• Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005; 59: 485–495
   PubMed Web of Science ®Google Scholar
• Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220–233
   PubMed Web of Science ®Google Scholar
• Ware JE, Kosinski M, Keller SD. How to Score the SF-12 Physical and Mental Health Summary Scales. The Health Institute, New England Medical Center, Boston, MA 1998
   Google Scholar
• West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 2005; 56: 283–291
   PubMed Web of Science ®Google Scholar
• Wieselgren IM, Lindstrom LH. A prospective 1–5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr Scand 1996; 93: 9–19
   PubMed Web of Science ®Google Scholar